Peptone is joining forces with IOR in Bellinzona to battle prostate cancer

Dr. Kamil Tamiola the CEO of Peptone Ltd and Prof. Andrea Alimonti, MD, Incoming Director, and Professor of Molecular Oncology at IOR as seen in The Institute of Oncology Research (IOR) in Bellinzona, Switzerland.

I am very excited to announce a collaborative sponsored research agreement with The Institute of Oncology Research (IOR) in Bellinzona, Switzerland, aimed at identifying and progressing novel targets in oncology to develop innovative medicines for prostate cancer patients.

The collaboration will employ translational models to focus on the identification and progression of novel targets in oncology. Peptone will combine its strength in targeting disordered proteins using generative machine learning, unique structural insights into disordered targets using the bespoke HDX-MS technology, and patient insights about cancer born out of the works of Prof. Alimonti’s group in Bellinzona.

The recent findings from Andrea's team demonstrate that advanced prostate cancer is regulated by several intrinsically disordered proteins, many of which can also control the tumour's immune response. Targeting those proteins could be a way to defeat this poorly curable disease.

What makes this deal even more exciting is the fact that Peptone and IOR are located in Ticino, Switzerland, and the collaboration is an excellent example of an efficient technology transfer process and a growing research and biotech ecosystem in the area.

You can read more from our website and official press release.